Pfizer Total Assets 1986-2025 | PFE
Pfizer total assets from 1986 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.
- Pfizer total assets for the quarter ending June 30, 2025 were $206.095B, a 4.67% decline year-over-year.
- Pfizer total assets for 2024 were $213.396B, a 5.79% decline from 2023.
- Pfizer total assets for 2023 were $226.501B, a 14.86% increase from 2022.
- Pfizer total assets for 2022 were $197.205B, a 8.67% increase from 2021.
Pfizer Annual Total Assets
(Millions of US $) |
| 2024 |
$213,396 |
| 2023 |
$226,501 |
| 2022 |
$197,205 |
| 2021 |
$181,476 |
| 2020 |
$154,229 |
| 2019 |
$167,594 |
| 2018 |
$159,422 |
| 2017 |
$171,797 |
| 2016 |
$171,615 |
| 2015 |
$167,381 |
| 2014 |
$167,566 |
| 2013 |
$172,101 |
| 2012 |
$185,798 |
| 2011 |
$188,002 |
| 2010 |
$195,014 |
| 2009 |
$212,949 |
| 2008 |
$111,148 |
| 2007 |
$115,268 |
| 2006 |
$115,546 |
| 2005 |
$116,970 |
| 2004 |
$123,078 |
| 2003 |
$116,775 |
| 2002 |
$46,356 |
| 2001 |
$39,153 |
| 2000 |
$33,510 |
| 1999 |
$20,574 |
| 1998 |
$18,302 |
| 1997 |
$15,336 |
| 1996 |
$14,667 |
| 1995 |
$12,729 |
| 1994 |
$11,099 |
| 1993 |
$9,331 |
| 1992 |
$9,590 |
| 1991 |
$9,635 |
| 1990 |
$9,052 |
| 1989 |
$8,325 |
| 1988 |
$7,638 |
| 1987 |
$6,923 |
| 1986 |
$5,228 |
| 1985 |
$4,463 |
Pfizer Quarterly Total Assets
(Millions of US $) |
| 2025-06-30 |
$206,095 |
| 2025-03-31 |
$208,028 |
| 2024-12-31 |
$213,396 |
| 2024-09-30 |
$219,476 |
| 2024-06-30 |
$216,193 |
| 2024-03-31 |
$221,095 |
| 2023-12-31 |
$226,501 |
| 2023-09-30 |
$215,021 |
| 2023-06-30 |
$220,168 |
| 2023-03-31 |
$195,617 |
| 2022-12-31 |
$197,205 |
| 2022-09-30 |
$195,350 |
| 2022-06-30 |
$195,290 |
| 2022-03-31 |
$183,841 |
| 2021-12-31 |
$181,476 |
| 2021-09-30 |
$179,188 |
| 2021-06-30 |
$169,920 |
| 2021-03-31 |
$158,818 |
| 2020-12-31 |
$154,229 |
| 2020-09-30 |
$178,983 |
| 2020-06-30 |
$177,934 |
| 2020-03-31 |
$166,336 |
| 2019-12-31 |
$167,594 |
| 2019-09-30 |
$170,446 |
| 2019-06-30 |
$156,199 |
| 2019-03-31 |
$155,421 |
| 2018-12-31 |
$159,422 |
| 2018-09-30 |
$167,838 |
| 2018-06-30 |
$164,980 |
| 2018-03-31 |
$164,612 |
| 2017-12-31 |
$171,797 |
| 2017-09-30 |
$172,151 |
| 2017-06-30 |
$168,558 |
| 2017-03-31 |
$168,784 |
| 2016-12-31 |
$171,615 |
| 2016-09-30 |
$178,430 |
| 2016-06-30 |
$170,658 |
| 2016-03-31 |
$162,929 |
| 2015-12-31 |
$167,381 |
| 2015-09-30 |
$170,867 |
| 2015-06-30 |
$160,878 |
| 2015-03-31 |
$160,640 |
| 2014-12-31 |
$167,566 |
| 2014-09-30 |
$171,362 |
| 2014-06-30 |
$172,612 |
| 2014-03-31 |
$171,808 |
| 2013-12-31 |
$172,101 |
| 2013-09-30 |
$175,521 |
| 2013-06-30 |
$179,335 |
| 2013-03-31 |
$187,398 |
| 2012-12-31 |
$185,798 |
| 2012-09-30 |
$182,603 |
| 2012-06-30 |
$182,842 |
| 2012-03-31 |
$185,683 |
| 2011-12-31 |
$188,002 |
| 2011-09-30 |
$196,132 |
| 2011-06-30 |
$195,899 |
| 2011-03-31 |
$194,956 |
| 2010-12-31 |
$195,014 |
| 2010-09-30 |
$191,415 |
| 2010-06-30 |
$191,071 |
| 2010-03-31 |
$195,113 |
| 2009-12-31 |
$212,949 |
| 2009-09-30 |
$141,294 |
| 2009-06-30 |
$139,339 |
| 2009-03-31 |
$122,932 |
| 2008-12-31 |
$111,148 |
| 2008-09-30 |
$115,249 |
| 2008-06-30 |
$116,515 |
| 2008-03-31 |
$118,550 |
| 2007-12-31 |
$115,268 |
| 2007-09-30 |
$109,030 |
| 2007-06-30 |
$110,403 |
| 2007-03-31 |
$110,483 |
| 2006-12-31 |
$115,546 |
| 2006-09-30 |
$108,585 |
| 2006-06-30 |
$111,550 |
| 2006-03-31 |
$112,959 |
| 2005-12-31 |
$116,970 |
| 2005-09-30 |
$110,343 |
| 2005-06-30 |
$112,327 |
| 2005-03-31 |
$122,935 |
| 2004-12-31 |
$123,078 |
| 2004-09-30 |
$122,229 |
| 2004-06-30 |
$119,961 |
| 2004-03-31 |
$122,289 |
| 2003-12-31 |
$116,775 |
| 2003-09-30 |
$120,058 |
| 2003-06-30 |
$124,258 |
| 2003-03-31 |
$52,928 |
| 2002-12-31 |
$46,356 |
| 2002-09-30 |
$44,876 |
| 2002-06-30 |
$42,568 |
| 2002-03-31 |
$41,316 |
| 2001-12-31 |
$39,153 |
| 2001-09-30 |
$38,806 |
| 2001-06-30 |
$36,941 |
| 2001-03-31 |
$35,146 |
| 2000-12-31 |
$33,510 |
| 2000-09-30 |
$33,488 |
| 2000-06-30 |
$32,044 |
| 2000-03-31 |
$20,225 |
| 1999-12-31 |
$20,574 |
| 1999-09-30 |
$20,239 |
| 1999-06-30 |
$19,640 |
| 1999-03-31 |
$19,025 |
| 1998-12-31 |
$18,302 |
| 1998-09-30 |
$18,177 |
| 1998-06-30 |
$16,508 |
| 1998-03-31 |
$15,955 |
| 1997-12-31 |
$15,336 |
| 1997-09-30 |
$15,347 |
| 1997-06-30 |
$15,732 |
| 1997-03-31 |
$15,053 |
| 1996-12-31 |
$14,667 |
| 1996-09-30 |
$14,616 |
| 1996-06-30 |
$13,619 |
| 1996-03-31 |
$13,174 |
| 1995-12-31 |
$12,729 |
| 1995-09-30 |
$12,821 |
| 1995-06-30 |
$12,945 |
| 1995-03-31 |
$12,515 |
| 1994-12-31 |
$11,099 |
| 1994-09-30 |
$10,402 |
| 1994-06-30 |
$10,100 |
| 1994-03-31 |
$9,641 |
| 1993-12-31 |
$9,331 |
| 1993-09-30 |
$9,882 |
| 1993-06-30 |
$10,019 |
| 1993-03-31 |
$9,724 |
| 1992-12-31 |
$9,590 |
| 1992-09-30 |
$10,130 |
| 1992-06-30 |
$9,555 |
| 1992-03-31 |
$9,468 |
| 1991-12-31 |
$9,635 |
| 1991-09-30 |
$9,008 |
| 1991-06-30 |
$8,826 |
| 1991-03-31 |
$8,814 |
| 1990-12-31 |
$9,052 |
| 1990-09-30 |
$8,530 |
| 1990-06-30 |
$8,100 |
| 1990-03-31 |
$7,955 |
| 1989-12-31 |
$8,325 |
| 1989-09-30 |
$7,726 |
| 1989-06-30 |
$7,654 |
| 1989-03-31 |
$7,600 |
| 1988-12-31 |
$7,638 |
| 1988-09-30 |
$7,295 |
| 1988-06-30 |
$7,204 |
| 1988-03-31 |
$6,963 |
| 1987-12-31 |
$6,923 |
| 1987-09-30 |
$5,828 |
| 1987-06-30 |
$5,716 |
| 1987-03-31 |
$5,385 |
| 1986-12-31 |
$5,228 |
| 1985-12-31 |
$4,463 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$201.199B |
$100.330B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
